Comparative Pharmacology
Head-to-head clinical analysis: ISOPROTERENOL HYDROCHLORIDE versus NORISODRINE AEROTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOPROTERENOL HYDROCHLORIDE versus NORISODRINE AEROTROL.
ISOPROTERENOL HYDROCHLORIDE vs NORISODRINE AEROTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-adrenergic agonist with non-selective affinity for β1 and β2 receptors; increases myocardial contractility, heart rate, and bronchodilation via Gs-protein activation and cAMP elevation.
Isoproterenol is a non-selective beta-adrenergic receptor agonist, primarily stimulating both β1 and β2 receptors, resulting in increased heart rate, myocardial contractility, and bronchodilation.
Initial IV infusion: 0.5-5 mcg/min, titrated to heart rate and blood pressure; typical range 2-10 mcg/min. IV bolus: 10-20 mcg as needed. Continuous infusion: 0.01-0.5 mcg/kg/min (max 30 mcg/min).
1 to 2 inhalations (0.08 to 0.16 mg) every 4 to 6 hours as needed for bronchospasm.
None Documented
None Documented
Terminal elimination half-life is 2-3 minutes; clinically, catechol-O-methyltransferase (COMT)-mediated metabolism leads to rapid clearance.
The terminal elimination half-life of isoproterenol is approximately 2-3 minutes following intravenous administration, due to rapid uptake into tissues and metabolism by catechol-O-methyltransferase (COMT). This short half-life necessitates continuous infusion for sustained effect.
Primarily renal excretion of sulfate conjugates and unchanged drug; biliary/fecal excretion is minimal.
Primarily renal excretion of unchanged drug and metabolites (sulfate conjugates). After intravenous administration, approximately 70-80% of the dose is excreted in urine within 24 hours, with less than 10% in feces.
Category C
Category C
Beta-Adrenergic Agonist
Beta-Adrenergic Agonist